2025年9月13日，在CSGCT大会“下一代免疫细胞疗法浪潮 - In Vivo CAR-T”分论坛上，一场关于细胞治疗未来的深度对话引发行业震动。昆翎医药联合创始人兼首席战略官、谱新生物联合创始人兼联席董事长张丹、华中科技大学同济医学院附属协和医院血液科主任医师梅 ...

Capstan的领先资产CPTX2309是一种靶向脂质纳米颗粒（tLNP），可将编码抗CD19嵌合抗原受体（CAR）的mRNA递送至体内表达CD8的细胞毒性T细胞，是治疗B细胞介导自身免疫性疾病的潜在同类首创产品。 B细胞在自身免疫性疾病的发病机制中起重要作用，CD19是表达在B细胞 ...

6月30日，AbbVie宣布以21亿美元现金收购Capstan Therapeutics，后者是一家致力于通过使用tLNP的RNA递送推进细胞体内工程的临床阶段生物技术公司。 根据该协议AbbVie将收购Capstan包括CPTX2309，一种潜在的同类首创体内tLNP抗CD19 CAR-T候选疗法，目前正处于1期，用于治疗B细胞 ...

June 30 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product ...

AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a “high-risk, high-reward” clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to $2.1 billion, expanding its pipeline with experimental treatments for ...

SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with ...

[Aaed Musa] has been building robot dogs for a long time now, so it was only natural that he would make one for the senior design project of his mechanical engineering degree. Since this meant working ...